Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.95) per share and revenue of $0.04 million for the quarter.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Viridian Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Down 8.3 %

Shares of NASDAQ VRDN opened at $12.03 on Wednesday. The stock has a market cap of $981.53 million, a PE ratio of -2.79 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The business has a fifty day moving average of $13.86 and a two-hundred day moving average of $17.73.

Wall Street Analysts Forecast Growth

A number of analysts have commented on VRDN shares. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.